Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI
Bristol-Myers Squibb Australia Pty Ltd
Bladder Cancer Muscle-Invasive Bladder Cancer
1 trial -
CLS2901C (human [allogeneic] chondrocyte sheets)
CellSeed Europe Ltd
Osteoarthritis of the Knee
1 trial -
CMP-001
Regeneron UK Limited
Melanoma
3 trials -
COAGULATION FACTOR VIII , COAGULATION FACTOR VIIA , COAGULATION FACTOR IX , SAR439774, FACTOR VIII INHIBITOR BYPASSING ACTIVITY , ANTITHROMBIN III
Genzyme Europe B.V.
Hemophilia A or Hemophilia B
1 trial -
COBALAMIN
The George Institute
Hydroxycobalamin deficiency
1 trial -
COLECALCIFEROL , PREDNISONE
Fondazione Telethon ETS
Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
CONDROSULF 800 mg tabletta
The George Institute
Knee osteoarthritis with moderate to severe pain
1 trial -
CONOXIA, gas medicinal comprimido, Conoxia 100% medicinal gas, cryogenic
The George Institute
ILD
1 trial -
COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance
The George Institute
Chronic liver disease
1 trial -
CORTANCYL 20 mg, comprimé sécable, Placebo of CORTANCYL 20 mg
Pari Pharma GmbH
Adults patients with isolated acute urticaria presenting to the emergency department
1 trial -
CORTANCYL 20 mg, comprimé sécable, placebo of Cortancyl 20 mg, NaCl 0,9% as placebo of kineret, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.
Pari Pharma GmbH
Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack
1 trial -
CP 751,871 (Figitumumab)
Pfizer
Carcinoma, Large Cell
1 trial -
CT-P55, Cosentyx 150 mg solution for injection in pre-filled syringe
Celltrion Healthcare Australia Pty Ltd
Plaque psoriasis
1 trial -
CYCLOPHOSPHAMIDE , -, PREDNISONE , PREDNISOLONE , VINCRISTINE, DOXORUBICIN , RITUXIMAB , Zilovertamab vedotin
Merck Sharp and Dohme
Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE
The George Institute
Acute Lymphoblastic Leukaemia
1 trial -
CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB
The George Institute
HER2-positive early breast cancer
1 trial -
CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, POMALIDOMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE, CYCLOPHOSPHAMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, POMALIDOMIDE, DARATUMUMAB, GPRC5D-TARGETED CAR T, DEXAMETHASONE SODIUM PHOSPHATE, POMALIDOMIDE, TOCILIZUMAB
Celgene Europe Limited
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
1 trial -
CYCLOPHOSPHAMIDE, Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion., DOXORUBICIN, DOCETAXEL
Ningbo Cancer Hospital
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
1 trial -
Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE
Lacuna Pharma Pty Ltd
Diffuse large B-cell lymphoma
1 trial -
Camrelizumab
The First People's Hospital of Lianyungang
Esophageal Cancer
2 trials -
Capecitabine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nasopharyngeal Carcinoma
1 trial -
Capecitabine Accord 150 mg film-coated tablets, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Irinotecan Accord 20 mg/ml Solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion
Ningbo Cancer Hospital
Stage III colorectal cancer
1 trial -
Capecitabine(Aibin)
The First People's Hospital of Lianyungang
Stage III Esophageal Squamous Cell Carcinoma
1 trial -
Carbetocin
United Therapeutics Europe Ltd
Post Partum Haemorrhage
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources